Eli Lilly and Company (LLY)vsRapid Micro Biosystems Inc (RPID)
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
RPID
Rapid Micro Biosystems Inc
$1.99
0.00%
HEALTHCARE · Cap: $99.14M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 210024% more annual revenue ($72.25B vs $34.38M). LLY leads profitability with a 35.0% profit margin vs -145.8%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
RPID
Avoid29
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : RPID
Revenue growth of 11.1% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : RPID
The primary concerns for RPID are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while RPID is a turnaround play — different risk/reward profiles.
RPID carries more volatility with a beta of 1.46 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 29/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Rapid Micro Biosystems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Rapid Micro Biosystems Inc (RPID) is an innovative biotechnology company focused on revolutionizing microbiological quality control processes within the pharmaceutical and biotechnology industries. Utilizing state-of-the-art automated growth-based microbial detection technologies, RPID significantly improves the accuracy and efficiency of microbial testing, which is vital for adhering to stringent regulatory standards. As demand for rapid and reliable quality assurance solutions continues to grow, Rapid Micro is well-positioned to drive advancements in testing methodologies that are essential for maintaining product safety and excellence in highly regulated environments.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?